SEC filings and other documents

Net income soared to $116.5M, fueled by investment gains and the Lifeward transaction.

Q1 2026 net income surged to $38.3M, fueled by investment gains and the Lifeward transaction.

2025 net income surged to $64M, fueled by investment gains and strategic asset transfers.

Net income reached $65M, assets rose 42%, and investment returns drove strong nine-month results.

Net income reached $5.6M in H1 2025, with strong financial income and diversified investments.

Q1 2025 net loss of $7.6M on $2.0M revenue, JV delayed, and major investments in Scilex and real estate.

Net loss of $19.1M in 2024, with a strategic shift to new clinical trials and diversified investments.

Net loss increased to $8.87M, with major strategic moves in financing, buybacks, and joint ventures.

Returned to profitability with $10.7M net income, strong cash, and new buyback and JV initiatives.